Latest news with #Bonerge
Yahoo
09-07-2025
- Business
- Yahoo
Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
NEW YORK, July 09, 2025--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A's potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances. Key Study Design Features: Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/ Assessment:Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction Continuous actigraphy monitoring, polysomnography (PSG) NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels. "We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration," stated Professor Chen, the lead investigator. "Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues." Scientific Commitment: Building a Health Ecosystem As a leading high-quality ingredient producer, Bonerge's R&D follows a pipeline of 'ingredient science, mechanistic research, clinical translation'. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A's potential in sleep health and cellular ageing intervention. Amidst the anti-ageing industry's shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust "health ecosystem." Key components include: Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health.L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis.S-Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health. About Bonerge Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at View source version on Contacts Cecilia Yangsales@ Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Business Wire
09-07-2025
- Health
- Business Wire
Bonerge Initiates Clinical Trial on Urolithin A and Fisetin for Sleep & Wellbeing
NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders through the lens of ageing biology. Bonerge's 12-week, quadruple-blind study evaluates how Urolithin A and Fisetin influence sleep via metabolic and epigenetic biomarkers. Share This randomized, quadruple-blind (participants, healthcare providers, researchers, assessors), placebo-controlled study will enroll over 80 participants aged 45-70. They will be divided into four groups: Urolithin A alone, Fisetin alone, Urolithin A + Fisetin combination, and placebo control. The 12-week intervention represents the first systematic evaluation of Urolithin A's potential to resynchronize circadian rhythms and mitigate age-related sleep disturbances. Key Study Design Features: Inclusion Criteria: Targets subclinical individuals with impaired sleep quality (PSQI score >5) but no pathological diagnosis, excluding those dependent on caffeine/alcohol. Multidimensional Assessment: Subjective: Sleep quality scores, chronotype questionnaire, daytime dysfunction scales. Objective: Continuous actigraphy monitoring, polysomnography (PSG) analysis. Biomarkers: NAD+ levels, DNA methylation age, inflammatory markers (IL-6, TNF-α), cortisol rhythm, circadian proteins (BMAL1, PER2), insulin resistance (HOMA-IR), immunoglobulin levels. "We aim to uncover the causal link between sleep disorders and ageing using epigenetic clocks and metabolic markers, beyond just tracking sleep duration," stated Professor Chen, the lead investigator. "Combining Urolithin A, a circadian regulator, with the senolytic Fisetin explores synergy for novel solutions, like menopausal sleep issues." Scientific Commitment: Building a Health Ecosystem As a leading high-quality ingredient producer, Bonerge's R&D follows a pipeline of 'ingredient science, mechanistic research, clinical translation'. The company is actively seeking global clinical partners from academia and industry to explore Urolithin A's potential in sleep health and cellular ageing intervention. Amidst the anti-ageing industry's shift from consumerism to scientific rigor, Bonerge positions Urolithin A not just as a standalone ingredient, but as a catalyst for evidence-based solutions. Focused on core mechanisms like cellular senescence, Bonerge develops innovative ingredients targeting cellular health, forming a robust "health ecosystem." Key components include: Fisetin: Potent senolytic selectively clearing senescent cells and reducing their formation, retarding aging in skin, ovarian, and neural tissues. Urolithin A: Regulates circadian rhythms, boosts endogenous NAD+ synthesis, enhances cellular repair, and improves sleep quality and reproductive health. L-Ergothioneine: Unique antioxidant with a dedicated transporter (OCTN1), accumulating in high-stress tissues to neutralize ROS, protecting DNA and telomeres. PQQ Disodium: Activates the PGC-1α/PPARγ pathway, driving mitochondrial DNA replication and biogenesis. S - Equol: Natural, non-steroidal estrogenic metabolite with high affinity for ERβ, offering a safer alternative for menopause health. About Bonerge Bonerge firmly contends that the future of anti-ageing hinges on evidence-based solutions. These solutions are grounded in well-defined biological mechanisms, supported by robust scientific data, and tailored to precise applications, ultimately delivering comprehensive, science-validated health benefits. For more detailed information about our clinical findings, discover more about us at
Associated Press
14-04-2025
- Business
- Associated Press
BeFisetin® Announced the Global No.1 All-Natural Fisetin With SA-GRAS Status
NEW YORK--(BUSINESS WIRE)--Apr 14, 2025-- Bonerge Lifescience, a trusted innovator in longevity ingredients, proudly announces a historic milestone: on April 2, 2025, its premium fisetin ingredient, BeFisetin ®, has achieved Self-affirmed Generally Recognized as Safe (SA-GRAS) status in the United States. This landmark accomplishment positions Bonerge as the first company globally to secure GRAS certification for fisetin powder, setting a new global benchmark for safety and reliability in the next-generation anti-aging market. This press release features multimedia. View the full release here: BeFisetin®: GRAS certified Fisetin for safe use in dietary supplements and health products. BeFisetin: Establishing the Gold Standard to Address Chaos in the Fisetin Market The current fisetin market is plagued by alarming quality inconsistencies. While vague claims of 'Fisetin 98% HPLC' dominate as the mainstream specification, actual fisetin content in these products ranges only between 75%-85%, with significant impurities concealed under this ambiguous standard. For plant extracts derived from non-edible sources, the removal of harmful components is critical. Fisetin, extracted from inedible Anacardiaceae plants, contains large amounts of toxic lacquer, waxes, and wood debris. Eliminating these impurities is essential to producing safe, high-quality fisetin. Yet, the absence of clear, stringent quality standards has made it impossible to verify purity, allowing low-quality products to flood the market. Many suppliers exploit rudimentary testing methods to falsely label products as '98% HPLC,' misleading consumers and perpetuating a cycle where inferior products overshadow genuine quality. This chaos forces brands to settle for subpar fisetin, stifling innovation in premium formulations. Establishing a gold standard for fisetin quality has been Bonerge's mission from the start. Recognizing the challenges—extensive R&D, industry-first breakthroughs, and short-term financial sacrifices—we named our product BeFisetin as a constant reminder: 'To be or not to be' hinges on our commitment to redefine excellence in fisetin. BeFisetin is not just a product—it's a pledge to restore integrity and drive progress in the fisetin industry. What Defines the Gold Standard for Fisetin? BeFisetin: The 1st All-Natural Fisetin to be Granted SA-GRAS BeFisetin ® is the first all-natural fisetin to attain SA-GRAS certification. For all dietary supplement ingredients, SA-GRAS represents a critical milestone, but its significance is unparalleled in advancing fisetin as a premium raw material. This certification sets the gold standard for the industry, requiring adherence to rigorous criteria: well-defined quality specifications, scientifically validated testing protocols, GMP-compliant manufacturing environments, and comprehensive safety assessments —all of which elevate fisetin from an underregulated botanical to a clinically trusted ingredient. By establishing these benchmarks, SA-GRAS not only ensures consumer safety but also paves the way for innovation in longevity-focused formulations. 'Beyond regulatory compliance, this accomplishment reflects our foundational commitment to scientific excellence and consumer safety—principles that drive every stage of our ingredient innovation,' stated Gloria, Product Manager of Bonerge. 'SA-GRAS BeFisetin ® provides brands with a scientifically validated ingredient that meets international regulatory requirements, enabling them to develop innovative products with assurance.' A Vision for Trusted Longevity Foundation The GRAS certification of BeFisetin ® marks the beginning of Bonerge's mission to redefine aging. By prioritizing rigorous science and consumer safety, Bonerge aims to foster transparency in the anti-aging market, and we are committed to providing scientifically grounded solutions that empower individuals to age healthily. As global interest in senotherapeutics grows, BeFisetin ® stands at the forefront, offering brands a trusted, scalable ingredient to meet the rising demand for effective and safe longevity products. View source version on CONTACT: Cecilia Yang [email protected] KEYWORD: UNITED STATES NORTH AMERICA NEW YORK INDUSTRY KEYWORD: HEALTH CONSUMER SENIORS FITNESS & NUTRITION RESEARCH SCIENCE VITAMINS/SUPPLEMENTS SOURCE: Bonerge Lifescience Copyright Business Wire 2025. PUB: 04/14/2025 04:38 AM/DISC: 04/14/2025 04:38 AM
